1. Home
  2. GGR vs IBIO Comparison

GGR vs IBIO Comparison

Compare GGR & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

HOLD

Current Price

$3.25

Market Cap

47.7M

ML Signal

HOLD

Logo iBio Inc.

IBIO

iBio Inc.

HOLD

Current Price

$2.82

Market Cap

50.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGR
IBIO
Founded
2011
2008
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.7M
50.4M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
GGR
IBIO
Price
$3.25
$2.82
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
10.8K
1.1M
Earning Date
01-01-0001
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
73.08
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.07
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.56
52 Week High
$6.21
$6.89

Technical Indicators

Market Signals
Indicator
GGR
IBIO
Relative Strength Index (RSI) 52.70 62.89
Support Level $2.96 $0.69
Resistance Level $3.46 $2.89
Average True Range (ATR) 0.14 0.22
MACD 0.04 0.06
Stochastic Oscillator 51.91 72.40

Price Performance

Historical Comparison
GGR
IBIO

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About IBIO iBio Inc.

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Share on Social Networks: